| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/17/2001 | WO2001034594A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | WO2001034574A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 05/17/2001 | WO2001034225A2 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 05/17/2001 | WO2001034208A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 05/17/2001 | WO2001034205A2 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | WO2001034204A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034203A1 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/17/2001 | WO2001034202A2 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 05/17/2001 | WO2001034201A2 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 05/17/2001 | WO2001034200A1 Body weight gain inhibitors |
| 05/17/2001 | WO2001034194A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | WO2001034179A1 Method of inducing angiogenesis |
| 05/17/2001 | WO2001034177A2 Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| 05/17/2001 | WO2001034176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | WO2001034174A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | WO2001034165A1 Therapeutic compositions and methods of use thereof |
| 05/17/2001 | WO2001034162A1 Anti-hiv compositions |
| 05/17/2001 | WO2001034161A1 A method of treating substance addiction |
| 05/17/2001 | WO2001034157A1 Protease inhibitors |
| 05/17/2001 | WO2001034149A1 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 05/17/2001 | WO2001034145A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | WO2001034140A1 Pharmaceutical formulation |
| 05/17/2001 | WO2001034139A1 Pharmaceutical formulation containing tolterodine and its use |
| 05/17/2001 | WO2001034138A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 05/17/2001 | WO2001034137A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034135A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034134A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034133A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034132A2 Use of an aldosterone antagonist for treating restenosis |
| 05/17/2001 | WO2001034131A2 Combination chemotherapy |
| 05/17/2001 | WO2001034130A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 05/17/2001 | WO2001034128A2 Admixture for intravenous administration of linezolid and other antibacterial agents |
| 05/17/2001 | WO2001034127A1 Prevention of plaque rupture by acat inhibitors |
| 05/17/2001 | WO2001034126A2 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| 05/17/2001 | WO2001034124A2 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system |
| 05/17/2001 | WO2001034119A2 Inhibitors of crystallization in a solid dispersion |
| 05/17/2001 | WO2001034118A2 Solid dispersion pharmaceutical formulations |
| 05/17/2001 | WO2001034117A1 A method for chemoprevention of prostate cancer |
| 05/17/2001 | WO2001034093A2 Potentiation of prodrug efficacy |
| 05/17/2001 | WO2001022955A3 Novel combination of loteprednol and antihistamines |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2001004157A3 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 05/17/2001 | WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/17/2001 | WO2001001932A3 Oligosaccharide aldonic acids and their topical use |
| 05/17/2001 | WO2000076499A3 Neuroprotective and retinoprotective ophthalmologic medicines |
| 05/17/2001 | WO2000040613A9 Insulin-like growth factor (igf) i mutant variants |
| 05/17/2001 | WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 05/17/2001 | WO1999048536A3 Delivery of long lasting therapeutic agents by forming covalent attachments in vivo |
| 05/17/2001 | WO1999044620A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/17/2001 | US20010001307 And mineral; for suppressing or ameliorating a symptom accompanying diminished homeostasis; having a reduced peculiar metal taste |
| 05/17/2001 | DE19954394A1 Verwendung von Polysiloxanen mit quartären Aminogruppen als Formulierungshilfe und Mittel enthalten dieselben Use of polysiloxanes with quaternary amino groups as a formulation aid and medium containing the same |
| 05/17/2001 | DE19953625A1 Verwendung von 5HT-1A Serotonin Rezeptor Agonisten zur Behandlung von genetischen oder funktionellen Atemrhythmusstörungen Use of 5-HT 1A serotonin receptor agonist for the treatment of genetic or functional respiratory arrhythmia |
| 05/17/2001 | CA2428827A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2391416A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2391278A1 Therapeutic compositions and methods of use thereof |
| 05/17/2001 | CA2391277A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | CA2390975A1 Potentiation of prodrug efficacy |
| 05/17/2001 | CA2390932A1 Body weight gain inhibitors |
| 05/17/2001 | CA2390789A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2390655A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 05/17/2001 | CA2390646A1 Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes |
| 05/17/2001 | CA2390561A1 Use of an aldosterone antagonist for treating restenosis |
| 05/17/2001 | CA2390501A1 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 05/17/2001 | CA2390412A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | CA2390374A1 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | CA2390231A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | CA2390128A1 Pharmaceutical formulation |
| 05/17/2001 | CA2390101A1 A method of treating substance addiction |
| 05/17/2001 | CA2389954A1 Method of inducing angiogenesis |
| 05/17/2001 | CA2389524A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 05/17/2001 | CA2389386A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | CA2389176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | CA2388918A1 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388644A1 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388343A1 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2386876A1 Combination chemotherapy |
| 05/17/2001 | CA2382676A1 Prevention of plaque rupture by acat inhibitors |
| 05/17/2001 | CA2359955A1 Human vanilloid receptor gene |
| 05/16/2001 | EP1099701A1 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B |
| 05/16/2001 | EP1099446A2 Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent |
| 05/16/2001 | EP1099444A1 Gastric acid secretion |
| 05/16/2001 | EP1099441A2 Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof |
| 05/16/2001 | EP1099439A2 Use of apo B secretion/MTP inhibitors |
| 05/16/2001 | EP1099438A2 Use of APO B secretion/MTP inhibitors |
| 05/16/2001 | EP1098981A1 A mutant human hepatitis b viral strain and uses thereof |
| 05/16/2001 | EP1098978A1 Gbs toxin receptor |
| 05/16/2001 | EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 05/16/2001 | EP1098962A2 Diacylglycerol acyl transferase proteins |
| 05/16/2001 | EP1098904A1 Axor10, a g-protein coupled receptor |
| 05/16/2001 | EP1098666A2 Water-soluble drugs and methods for their production |
| 05/16/2001 | EP1098665A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 05/16/2001 | EP1098662A2 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 05/16/2001 | EP1098652A2 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
| 05/16/2001 | EP1098645A1 Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ards) and infant respiratory distress syndrome (irds) |
| 05/16/2001 | EP1098642A1 Methods for treating conditions modulated by lactosylceramide |